BeStock  
Stocks › Biotechnology › TRVI

Trevi Therapeutics TRVI

US equityMarket cap rank #2705Biotechnology
$13.35 −$0.37 (-2.70%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $13.35 0.00%
Open$13.58
Prev close$13.72
Day range$13.23 – $13.90
Volume2.09M
Market cap$1.90B
P/E (TTM)–
Dividend yield–

Valuation

Multiples measured against the stock's own five-year history

Price / earnings-34.1x
CheapRich

Near the bottom of its 5-year range · 14th percentile, 5-year average -14.4x

Price / book6.4x
CheapRich

Above its usual level · 69th percentile, 5-year average 4.8x

#4638 of 5335 stocks by PB (1 = cheapest)

P/E over five years

-66x-42x-18x5xOct '21Apr '24Nov '26

Dashed line is the 5-year average; the shaded band is one standard deviation either side.

Morningstar fair value estimate

Fair value$16.45
Price vs. fair value-18.8%Trading below the estimate
Star rating★★★☆☆
Economic moatNone
UncertaintyVery High
MultipleCurrentForward5y averagePercentile vs. own historyIndustry rank
PB 6.43 – 4.76 69% (pricier than usual) #4638 of 5335 (1 = cheapest)
PE -34.13 -17.06 -14.36 14% (cheaper than usual) –
PS – – 0.00 – –

Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.

Discussion

No comments yet — be the first to weigh in on TRVI.

Sign in to join the discussion.

Scroll to Top